{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:38:56Z","timestamp":1771472336676,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,1,22]],"date-time":"2012-01-22T00:00:00Z","timestamp":1327190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s10549-012-1957-0","type":"journal-article","created":{"date-parts":[[2012,1,21]],"date-time":"2012-01-21T04:09:50Z","timestamp":1327118990000},"page":"257-265","source":"Crossref","is-referenced-by-count":35,"title":["Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer"],"prefix":"10.1007","volume":"133","author":[{"given":"Else","family":"Maae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorte Aalund","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina Dahl","family":"Steffensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik Hugger","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Brandslund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flemming Brandt","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,22]]},"reference":[{"key":"1957_CR1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182\u20131186","journal-title":"N Engl J Med"},{"key":"1957_CR2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/74651","volume":"6","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389\u2013395","journal-title":"Nat Med"},{"key":"1957_CR3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676","journal-title":"Nat Med"},{"key":"1957_CR4","doi-asserted-by":"crossref","first-page":"9267","DOI":"10.1073\/pnas.88.20.9267","volume":"88","author":"D Maglione","year":"1991","unstructured":"Maglione D, Guerriero V, Viglietto G, li-Bovi P, Persico MG (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267\u20139271","journal-title":"Proc Natl Acad Sci USA"},{"key":"1957_CR5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nrc2524","volume":"8","author":"C Fischer","year":"2008","unstructured":"Fischer C, Mazzone M, Jonckx B, Carmeliet P (2008) FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8:942\u2013956","journal-title":"Nat Rev Cancer"},{"key":"1957_CR6","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.ejca.2005.07.022","volume":"41","author":"C Parr","year":"2005","unstructured":"Parr C, Watkins G, Boulton M, Cai J, Jiang WG (2005) Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 41:2819\u20132827","journal-title":"Eur J Cancer"},{"key":"1957_CR7","first-page":"537","volume":"23","author":"A Escudero-Esparza","year":"2010","unstructured":"Escudero-Esparza A, Martin TA, Douglas-Jones A, Mansel RE, Jiang WG (2010) PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance. Oncol Rep 23:537\u2013544","journal-title":"Oncol Rep"},{"key":"1957_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2004.05.020","volume":"213","author":"CN Chen","year":"2004","unstructured":"Chen CN, Hsieh FJ, Cheng YM, Cheng WF, Su YN, Chang KJ et al (2004) The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 213:73\u201382","journal-title":"Cancer Lett"},{"key":"1957_CR9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/gut.2004.050831","volume":"54","author":"SC Wei","year":"2005","unstructured":"Wei SC, Tsao PN, Yu SC, Shun CT, Tsai-Wu JJ, Wu CH et al (2005) Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 54:666\u2013672","journal-title":"Gut"},{"key":"1957_CR10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2006.10.005","volume":"250","author":"MC Ho","year":"2007","unstructured":"Ho MC, Chen CN, Lee H, Hsieh FJ, Shun CT, Chang CL et al (2007) Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 250:237\u2013249","journal-title":"Cancer Lett"},{"key":"1957_CR11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.athoracsur.2009.04.038","volume":"88","author":"E Pompeo","year":"2009","unstructured":"Pompeo E, Albonici L, Doldo E, Orlandi A, Manzari V, Modesti A et al (2009) Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. Ann Thorac Surg 88:426\u2013431","journal-title":"Ann Thorac Surg"},{"key":"1957_CR12","first-page":"1647","volume":"23","author":"S Nagaoka","year":"2010","unstructured":"Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Hisamoto T, Yoshida Y et al (2010) The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol Rep 23:1647\u20131654","journal-title":"Oncol Rep"},{"key":"1957_CR13","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/hed.21335","volume":"32","author":"SJ Cheng","year":"2010","unstructured":"Cheng SJ, Lee JJ, Kok SH, Chou CH, Chang HH, Chiang ML et al (2010) Expression of placenta growth factor: an independent factor for prediction of progression and prognosis of oral cancer. Head Neck 32:1363\u20131369","journal-title":"Head Neck"},{"key":"1957_CR14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nm731","volume":"8","author":"A Luttun","year":"2002","unstructured":"Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F et al (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8:831\u2013840","journal-title":"Nat Med"},{"key":"1957_CR15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/87904","volume":"7","author":"P Carmeliet","year":"2001","unstructured":"Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De MM et al (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575\u2013583","journal-title":"Nat Med"},{"key":"1957_CR16","doi-asserted-by":"crossref","first-page":"25646","DOI":"10.1016\/S0021-9258(18)47298-5","volume":"269","author":"JE Park","year":"1994","unstructured":"Park JE, Chen HH, Winer J, Houck KA, Ferrara N (1994) Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1\/KDR. J Biol Chem 269:25646\u201325654","journal-title":"J Biol Chem"},{"key":"1957_CR17","first-page":"4129","volume":"59","author":"WL Monsky","year":"1999","unstructured":"Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP et al (1999) Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 59:4129\u20134135","journal-title":"Cancer Res"},{"key":"1957_CR18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2353\/ajpath.2006.051041","volume":"169","author":"M Marcellini","year":"2006","unstructured":"Marcellini M, De LN, Riccioni T, Ciucci A, Orecchia A, Lacal PM et al (2006) Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am J Pathol 169:643\u2013654","journal-title":"Am J Pathol"},{"key":"1957_CR19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/sj.bjc.6605746","volume":"103","author":"AP Taylor","year":"2010","unstructured":"Taylor AP, Leon E, Goldenberg DM (2010) Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1\/2 phosphorylation and cytoskeletal rearrangement. Br J Cancer 103:82\u201389","journal-title":"Br J Cancer"},{"key":"1957_CR20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1050-1738(02)00168-8","volume":"12","author":"FS De","year":"2002","unstructured":"De FS, Gigante B, Persico MG (2002) Structure and function of placental growth factor. Trends Cardiovasc Med 12:241\u2013246","journal-title":"Trends Cardiovasc Med"},{"key":"1957_CR21","doi-asserted-by":"crossref","first-page":"26988","DOI":"10.1016\/S0021-9258(18)47116-5","volume":"269","author":"J Waltenberger","year":"1994","unstructured":"Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988\u201326995","journal-title":"J Biol Chem"},{"key":"1957_CR22","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm884","volume":"9","author":"M Autiero","year":"2003","unstructured":"Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D et al (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9:936\u2013943","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"1957_CR23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1634\/theoncologist.5-suppl_1-37","volume":"5","author":"G Gasparini","year":"2000","unstructured":"Gasparini G (2000) Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5(Suppl 1):37\u201344","journal-title":"Oncologist"},{"key":"1957_CR24","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","volume":"97","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). J Natl Cancer Inst 97:1180\u20131184","journal-title":"J Natl Cancer Inst"},{"key":"1957_CR25","doi-asserted-by":"crossref","unstructured":"Elston CW and Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19; 403\u2013410. Histopathology 41:151\u2013152","DOI":"10.1046\/j.1365-2559.2002.14691.x"},{"key":"1957_CR26","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2002.02.026","volume":"20","author":"SE Singletary","year":"2002","unstructured":"Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI et al (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628\u20133636","journal-title":"J Clin Oncol"},{"key":"1957_CR27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","volume":"131","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18\u201343","journal-title":"Arch Pathol Lab Med"},{"key":"1957_CR28","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","volume":"25","author":"CA Hudis","year":"2007","unstructured":"Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127\u20132132","journal-title":"J Clin Oncol"},{"key":"1957_CR29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cloc.2011.04.007","volume":"4","author":"MP Smerdel","year":"2011","unstructured":"Smerdel MP, Steffensen KD, Waldst\u00f8m M, Andersen RF, Olsen DA, Brandslund I et al (2011) VEGF in the development of ovarian malignancy. Clinical Ovarian Cancer 4:19\u201325","journal-title":"Clinical Ovarian Cancer"},{"key":"1957_CR30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1515\/CCLM.2007.034","volume":"45","author":"DA Olsen","year":"2007","unstructured":"Olsen DA, Ostergaard B, Bokmand S, Wamberg PA, Jakobsen EH, Brandslund I (2007) HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clin Chem Lab Med 45:177\u2013182","journal-title":"Clin Chem Lab Med"},{"key":"1957_CR31","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","volume":"28","author":"DW Miles","year":"2010","unstructured":"Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239\u20133247","journal-title":"J Clin Oncol"},{"key":"1957_CR32","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666\u20132676","journal-title":"N Engl J Med"},{"key":"1957_CR33","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252\u20131260","journal-title":"J Clin Oncol"},{"key":"1957_CR34","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1073\/pnas.1109029108","volume":"108","author":"J Yao","year":"2011","unstructured":"Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, Phan V et al (2011) Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci USA 108:11590\u201311595","journal-title":"Proc Natl Acad Sci USA"},{"key":"1957_CR35","author":"U Lassen","year":"2009","unstructured":"Lassen U, Nielsen D, S\u00f8rensen M, R\u00f8nnengart E, Eldrup K, Bentzon K et al (2009) A dose escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with solid tumors. Mol Cancer Ther. doi: 10.1158\/1535-7163.TARG-09-A111","journal-title":"Mol Cancer Ther"},{"key":"1957_CR36","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.clinthera.2011.08.007","volume":"33","author":"T Martinsson-Niskanen","year":"2011","unstructured":"Martinsson-Niskanen T, Riisbro R, Larsson L, Winstedt L, Stenberg Y, Pakola S et al (2011) Monoclonal antibody TB-403: A first-in-human, phase i, double-blind, dose escalation study directed against placental growth factor in healthy male subjects. Clin Ther 33:1142\u20131149","journal-title":"Clin Ther"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-1957-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-1957-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-1957-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T17:49:18Z","timestamp":1640540958000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-1957-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,22]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["1957"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-1957-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,22]]}}}